Literature DB >> 26371841

Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization.

Amedee Renand1, Luis D Archila1, John McGinty1, Erik Wambre1, David Robinson2, Belinda J Hales3, Wayne R Thomas3, William W Kwok4.   

Abstract

BACKGROUND: In human subjects, allergen tolerance has been observed after high-dose allergen exposure or after completed allergen immunotherapy, which is related to the accumulation of anti-inflammatory IgG4. However, the specific T-cell response that leads to IgG4 induction during chronic allergen exposure remains poorly understood.
OBJECTIVE: We sought to evaluate the relationship between cat allergen-specific T-cell frequency, cat allergen-specific IgE and IgG4 titers, and clinical status in adults with cat allergy with and without cat ownership and the cellular mechanism by which IgG4 is produced.
METHODS: Fel d 1-, Fel d 4-, Fel d 7-, and Fel d 8-specific T-cell responses were characterized by CD154 expression after antigen stimulation.
RESULTS: In allergic subjects without cat ownership, the frequency of cat allergen (Fel d 1 and Fel d 4)-specific TH2 (sTH2) cells correlates with higher IgE levels and is linked to asthma. Paradoxically, we observed that subjects with cat allergy and chronic cat exposure maintain a high frequency of sTH2 cells, which correlates with higher IgG4 levels and low sensitization. B cells from allergic, but not nonallergic subjects, are able to produce IgG4 after cognate interactions with sTH2 clones and Fel d 1 peptide or the Fel d 1 recombinant protein.
CONCLUSION: These experiments suggest that (1) allergen-experienced B cells with the capacity to produce IgG4 are present in allergic subjects and (2) cat allergen exposure induces an IgG4 response in a TH2 cell-dependent manner. Thus IgG4 accumulation could be mediated by chronic activation of the TH2 response, which in turn drives desensitization.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Entities:  

Keywords:  CD154; Cat allergy; Fel d 1; Fel d 4; IgG(4); T(H)2 cells; allergen exposure; allergen tolerance; asthma; class II tetramer

Mesh:

Substances:

Year:  2015        PMID: 26371841      PMCID: PMC4679456          DOI: 10.1016/j.jaci.2015.07.031

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  45 in total

Review 1.  Immunoglobulin class-switch DNA recombination: induction, targeting and beyond.

Authors:  Zhenming Xu; Hong Zan; Egest J Pone; Thach Mai; Paolo Casali
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

2.  Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

Authors:  Louisa K James; Mohamed H Shamji; Samantha M Walker; Duncan R Wilson; Petra A Wachholz; James N Francis; Mikila R Jacobson; Ian Kimber; Stephen J Till; Stephen R Durham
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

3.  Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.

Authors:  Christian Möbs; Henrik Ipsen; Lea Mayer; Caroline Slotosch; Arnd Petersen; Peter A Würtzen; Michael Hertl; Wolfgang Pfützner
Journal:  J Allergy Clin Immunol       Date:  2012-09-27       Impact factor: 10.793

Review 4.  Innate B cell helpers reveal novel types of antibody responses.

Authors:  Carola G Vinuesa; Pheh-Ping Chang
Journal:  Nat Immunol       Date:  2013-01-18       Impact factor: 25.606

5.  Two newly identified cat allergens: the von Ebner gland protein Fel d 7 and the latherin-like protein Fel d 8.

Authors:  W Smith; S E O'Neil; B J Hales; T L Y Chai; L A Hazell; S Tanyaratsrisakul; S Piboonpocanum; W R Thomas
Journal:  Int Arch Allergy Immunol       Date:  2011-05-17       Impact factor: 2.749

6.  Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy.

Authors:  Erik Wambre; Jonathan H DeLong; Eddie A James; Rebecca E LaFond; David Robinson; William W Kwok
Journal:  J Allergy Clin Immunol       Date:  2011-10-05       Impact factor: 10.793

Review 7.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.

Authors:  Andrea Cerutti; Montserrat Cols; Irene Puga
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

Review 8.  New paradigms in type 2 immunity.

Authors:  Bali Pulendran; David Artis
Journal:  Science       Date:  2012-07-27       Impact factor: 47.728

9.  Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.

Authors:  Louisa K James; Holly Bowen; Rosaleen A Calvert; Tihomir S Dodev; Mohamed H Shamji; Andrew J Beavil; James M McDonnell; Stephen R Durham; Hannah J Gould
Journal:  J Allergy Clin Immunol       Date:  2012-05-13       Impact factor: 10.793

Review 10.  B cell TLRs and induction of immunoglobulin class-switch DNA recombination.

Authors:  Egest J Pone; Zhenming Xu; Clayton A White; Hong Zan; Paolo Casali
Journal:  Front Biosci (Landmark Ed)       Date:  2012-06-01
View more
  12 in total

Review 1.  Immunotherapy for pet allergies.

Authors:  Tuomas Virtanen
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

Review 2.  Pathogenic CD4+ T cells in patients with asthma.

Authors:  Lyndsey M Muehling; Monica G Lawrence; Judith A Woodfolk
Journal:  J Allergy Clin Immunol       Date:  2017-04-22       Impact factor: 10.793

3.  Synchronous immune alterations mirror clinical response during allergen immunotherapy.

Authors:  Amedee Renand; Mohamed H Shamji; Kristina M Harris; Tielin Qin; Erik Wambre; Guy W Scadding; Peter A Wurtzen; Stephen J Till; Alkis Togias; Gerald T Nepom; William W Kwok; Stephen R Durham
Journal:  J Allergy Clin Immunol       Date:  2017-11-09       Impact factor: 10.793

Review 4.  House Dust Mite Allergens: New Discoveries and Relevance to the Allergic Patient.

Authors:  Wayne R Thomas
Journal:  Curr Allergy Asthma Rep       Date:  2016-09       Impact factor: 4.806

Review 5.  Effect of allergen-specific immunotherapy on CD4+ T cells.

Authors:  Erik Wambre
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-12

6.  Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

Authors:  Elisa Masat; Pascal Laforêt; Marie De Antonio; Guillaume Corre; Barbara Perniconi; Nadjib Taouagh; Kuberaka Mariampillai; Damien Amelin; Wladimir Mauhin; Jean-Yves Hogrel; Catherine Caillaud; Giuseppe Ronzitti; Francesco Puzzo; Klaudia Kuranda; Pasqualina Colella; Roberto Mallone; Olivier Benveniste; Federico Mingozzi
Journal:  Sci Rep       Date:  2016-11-04       Impact factor: 4.379

7.  Cross-sectional study on sensitization to mite and cockroach allergen components in allergy patients in the Central European region.

Authors:  Petr Panzner; Martina Vachová; Tomáš Vlas; Petra Vítovcová; Petra Brodská; Marek Malý
Journal:  Clin Transl Allergy       Date:  2018-06-04       Impact factor: 5.871

8.  Heterogeneity of Ara h Component-Specific CD4 T Cell Responses in Peanut-Allergic Subjects.

Authors:  Amedee Renand; Marry Farrington; Elizabeth Whalen; Erik Wambre; Veronique Bajzik; Sharon Chinthrajah; Kari C Nadeau; William W Kwok
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

Review 9.  An Overview of the Relevance of IgG4 Antibodies in Allergic Disease with a Focus on Food Allergens.

Authors:  Thomas A E Platts-Mills; Behnam Keshavarz; Jeffrey M Wilson; Rung-Chi Li; Peter W Heymann; Diane R Gold; Emily C McGowan; Elizabeth A Erwin
Journal:  Children (Basel)       Date:  2021-05-20

Review 10.  The future outlook on allergen immunotherapy in children: 2018 and beyond.

Authors:  Stefania Arasi; Giovanni Corsello; Alberto Villani; Giovanni Battista Pajno
Journal:  Ital J Pediatr       Date:  2018-07-11       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.